K. Hellström

发表

K. Hellström, I. Hellström, 1990 .

Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience.

S. Larson, J. Carrasquillo, K. Krohn, 1985, Radiology.

Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts.

E. Neuwelt, K. Hellström, I. Hellström, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.

Z. Ye, G. Goodman, I. Hellstrom, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Imaging of melanoma with L-131-labeled monoclonal antibodies.

S. Larson, J. Brown, J. Carrasquillo, 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Michèl Schummer, Nicole Urban, M. Schummer, 2003, Cancer research.

In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.

L. Chen, K. Hellström, G. Yang, 1995, Journal of immunology.

Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system.

S. Larson, E. Neuwelt, K. Hellström, 1987, Neurosurgery.

Possibilities for active immunotherapy of human cancer.

I. Hellstrom, K. Hellström, I. Hellström, 1992, Cancer investigation.

Therapeutic Use of Antimelanoma Monoclonal Antibodies

I. Hellstrom, K. Hellström, 1988 .

Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes

J. Johnston, L. Chen, K. Hellström, 1996, The Journal of experimental medicine.

Cellular and Humoral immunity to Different Types of Human Neoplasms

K. Hellström, I. Hellström, G. Pierce, 1968, Nature.

Immunological Ignorance of an E 7-Encoded Cytolytic T-Lymphocyte Epitope in Transgenic Mice Expressing the E 7 and E 6 Oncogenes of Human Papillomavirus Type 16

Lieping Chen, I. Melero, H. Haugen, 1997 .

Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.

A. Dahlin, K. Knutson, M. Disis, 2003, Molecular cancer therapeutics.

Amplification of tumor immunity by gene transfer of the co‐stimulatory 4‐1BB ligand: synergy with the CD28 co‐stimulatory pathway

Lieping Chen, A. Aruffo, K. Hellström, 1998, European journal of immunology.

Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models

S. Tuve, S. Roffler, A. Lieber, 2011, Cancer Gene Therapy.

Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.

Z. Ye, A. Lieber, K. Hellström, 2007, Cancer research.

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.

N. D. Di Paolo, S. Tuve, S. Ni, 2006, Cancer research.

Responses Cyclophosphamide Treatment on Antitumor Immune Expression and Oncolysis in Combination with Low-Dose Effect of Adenovirus-Mediated Heat Shock Protein

S. Tuve, S. Ni, A. Lieber, 2006 .

Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen.

L. Chen, I. Hellstrom, K. Hellström, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Generation of cytotoxic agents by targeted enzymes.

D. Kerr, K. Hellström, I. Hellström, 1993, Bioconjugate chemistry.

Cell surface antigens of human melanoma identified by monoclonal antibody.

J. Brown, J. Hansen, I. Hellstrom, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate.

D. Kerr, K. Hellström, I. Hellström, 1993, Bioconjugate chemistry.

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

P. Linsley, Lieping Chen, J. Ledbetter, 1992, Cell.

Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis.

J. Bajorath, W. Huse, K. Hellström, 1995, Journal of immunology.

Antioxidant-induced changes in oxidized DNA

Paul M Johnson, K. Hellström, D. C. Malins, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2.

S. Hakomori, R. Kannagi, S. Levery, 1982, The Journal of biological chemistry.

Mouse monoclonal antibodies with specificity for the melanoma-associated ganglioside disialyllactosylceramide (GD3) also react with the structural analogue disialylparagloboside.

H. Sjögren, K. Karlsson, K. Hellström, 1985, Biochimica et biophysica acta.

Demonstration of cell‐mediated immunity to human neoplasms of various histological types

H. Sjögren, K. Hellström, I. Hellström, 1971, International journal of cancer.

Destruction of cultivated melanoma cells by lymphocytes from healthy black (North American Negro) donors

H. Sjögren, I. Hellstrom, K. Hellström, 1973, International journal of cancer.

Synthesis and antitumor activity of the immunoconjugate BR96-Dox

P. Trail, K. Hellström, I. Hellström, 1996 .

Radioimmunoscintigraphy by Means of Melanoma Antibody

S. Larson, J. Carrasquillo, J. Reynolds, 1986 .

Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide

D. Kerr, K. Hellström, I. Hellström, 2005, Cancer Immunology, Immunotherapy.

Homologous recombination in hybridoma cells: heavy chain chimeric antibody produced by gene targeting.

H. P. Fell, K. Folger, K. Hellström, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes

J. Anderson, K. Hellström, I. Hellström, 1994, The Journal of cell biology.

Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16.

D. Galloway, L. Chen, K. Hellström, 1992, Journal of immunology.

Carcinoma Monoclonal Mouse Antibodies Raised against Human Lung Updated

Immunology, P. Linsley, J. Brown, 2006 .

Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer.

G. Goodman, K. Hellström, I. Hellström, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Silencing of the TGF-&bgr;1 Gene Increases the Immunogenicity of Cells From Human Ovarian Carcinoma

E. Swisher, K. Agnew, Pu Liu, 2012, Journal of immunotherapy.

The influence of periodate oxidation on monoclonal antibody avidity and immunoreactivity.

K. Hellström, I. Hellström, D. Gabel, 1991, Journal of immunological methods.

Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence.

W. Dreyer, D. Teplow, J. Brown, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies.

J. Brown, I. Hellstrom, K. Hellström, 1981, Journal of immunology.

Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy.

S. Larson, M. Graham, J. Brown, 1983, The Journal of clinical investigation.

Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens.

K. Hellström, I. Hellström, Ursula Garrigues, 1990, Cancer research.

Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.

K. Hellström, I. Hellström, J. Bryan, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.

P. Trail, T. Doyle, I. Hellstrom, 1997, Cancer research.

Cloning and expression of the gene for the melanoma-associated ME20 antigen.

A. Aruffo, K. Hellström, I. Hellström, 1994, DNA and cell biology.

Drug immunotargeting for carcinomas: a reality at last?

P. Trail, K. Hellström, A. Casazza, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Crystallization and preliminary X-ray analysis of the monoclonal anti-tumor antibody BR96 and its complex with the Lewis Y determinant.

J. Bajorath, P. Jeffrey, S. Sheriff, 1994, Journal of molecular biology.

Ley specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes.

K. Hellström, I. Hellström, Ursula Garrigues, 1993, The American journal of pathology.

An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice.

G. Schreiber, I. Hellstrom, K. Hellström, 1992, Cancer research.

Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside.

I. Hellstrom, K. Hellström, I. Hellström, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Epitope mapping and use of anti-idiotypic antibodies to the L6 monoclonal anticarcinoma antibody.

H. P. Fell, M. Gayle, M. Kahn, 1990, Cancer research.

Antitumor antibodies for therapy.

K. Hellström, I. Hellström, 1989, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.

G. Schreiber, K. Hellström, I. Hellström, 1989, Cancer research.

Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates.

P. Trail, K. Hellström, H. D. King, 1999, Bioconjugate chemistry.

In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats.

K. Hellström, I. Hellström, D. Chace, 1994, Journal of immunology.

Chimeric L6 anti-tumor antibody. Genomic construction, expression, and characterization of the antigen binding site.

H. P. Fell, M. Gayle, J. Bajorath, 1992, The Journal of biological chemistry.

Membrane topology of the L6 antigen and identification of the protein epitope recognized by the L6 monoclonal antibody.

J. Bajorath, G. Schieven, A. Aruffo, 1994, The Journal of biological chemistry.

Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.

R. R. Robinson, I. Hellstrom, K. Hellström, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.

N. Siemers, D. Kerr, K. Hellström, 1997, Bioconjugate chemistry.

The National Institutes of Health Experience with Radiolabeled Monoclonal Antibodies: Lymphoma, Melanoma, and Colon Cancer

S. Larson, J. Mulshine, J. Schlom, 1988 .

Pilot trial of murine monoclonal antibodies in patients with advanced melanoma.

G. Goodman, I. Hellstrom, K. Hellström, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Studies of a high molecular weight human melanoma-associated antigen.

J. Brown, K. Hellström, I. Hellström, 1983, Journal of immunology.

Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues.

J. Brown, I. Hellstrom, K. Hellström, 1981, Proceedings of the National Academy of Sciences of the United States of America.

High-level iodination of monoclonal antibody fragments for radiotherapy.

S. Larson, J. Brown, J. Carrasquillo, 1984, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.

R. R. Robinson, J. Ledbetter, K. Hellstrom, 1987, Journal of immunology.

Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.

L. Chen, K. Hellström, I. Hellström, 1995, Journal of immunology.

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

G. Schreiber, J. Brown, I. Hellstrom, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates.

P. Su, T. Sakai, T. Katsuragi, 1991, Bioconjugate chemistry.

The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface

M. Lark, K. Hellström, I. Hellström, 1986, The Journal of cell biology.

Demonstration of cell-bound and humoral immunity against neuroblastoma cells.

I. Hellstrom, K. Hellström, I. Hellström, 1968, Proceedings of the National Academy of Sciences of the United States of America.

Arterial chondroitin sulfate proteoglycan: localization with a monoclonal antibody.

M. Lark, K. Hellstrom, K. Hellström, 1988, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Activation of prodrugs by targeted enzymes.

K. Hellström, P. Senter, 1991, European journal of cancer.

Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments.

S. Larson, J. Brown, J. Carrasquillo, 1984, Cancer treatment reports.

Evaluation of L6, an anti-carcinoma murine monoclonal antibody, in tumor-bearing nude mice.

E. Lavie, K. Hellström, I. Hellström, 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Immunoreactivity assay for labeled anti-melanoma monoclonal antibodies.

J. Eary, W. Nelp, K. Krohn, 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Autoradiolysis of iodinated monoclonal antibody preparations.

J. Eary, W. Nelp, K. Krohn, 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Diagnostic and therapeutic use of monoclonal antibodies to human tumor antigens

J. Brown, K. Hellström, I. Hellström, 1984, Medical oncology and tumor pharmacotherapy.

Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms.

J. Brown, I. Hellstrom, K. Hellström, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Use of monoclonal antibodies for quantitative analysis of antigens in normal and neoplastic tissues.

J. Brown, K. Hellström, I. Hellström, 1981, Clinical chemistry.

Monoclonal antibodies to human melanoma antigens-Possible clinical applications

S. Larson, K. Hellström, I. Hellström, 1983 .

Melanoma localization in nude mice with monoclonal Fab against p97.

S. Larson, J. Eary, W. Nelp, 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Cell surface phenotypes of radiolabeled immune long-lived lymphocytes that selectively localize in syngeneic tumours.

J. Mulé, I. Hellstrom, K. Hellstrom, 1982, The American journal of pathology.

Selective localization of radiolabeled immune lymphocytes into syngeneic tumors.

J. Mulé, K. Hellström, I. Hellström, 1979, Journal of immunology.

Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption.

E. Neuwelt, K. Hellstrom, K. Hellström, 1988, Cancer research.

CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.

H. Sugawara, K. Okuno, P. Greenberg, 1991, Journal of immunology.

Cellular immunity against tumor antigens.

K. Hellström, I. Hellström, 1969, Advances in cancer research.

A cell‐surface antigen which is present in the ganglioside fraction and shared by human melanomas

S. Hakomori, I. Hellstrom, K. Hellström, 1982, International journal of cancer.

Monoclonal antibodies to two mouse bladder carcinoma antigens

K. Hellström, I. Hellström, W. Chapman, 1982 .

Analysis of normal neoplastic human tissues for the tumor‐associated protein p97

K. Hellström, I. Hellström, Joseph P. Brown, 1981, International journal of cancer.

Granule membrane protein 140 (GMP140) binds to carcinomas and carcinoma-derived cell lines.

A. Aruffo, K. Hellström, I. Hellström, 1992, Proceedings of the National Academy of Sciences of the United States of America.

HER4 Expression Correlates with Cytotoxicity Directed by a Heregulin-Toxin Fusion Protein (*)

H. P. Fell, B. D. Cohen, G. Plowman, 1995, The Journal of Biological Chemistry.

CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer

Z. Ye, G. Goodman, J. Ledbetter, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Regressions and cures of melanoma xenografts following treatment with monoclonal antibody beta-lactamase conjugates in combination with anticancer prodrugs.

G. Schreiber, D. Kerr, K. Hellström, 1995, Cancer research.

Allogeneic inhibition of transplanted tumor cells.

K. Hellström, I. Hellström, 1967, Progress in experimental tumor research.

Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB

A. Dahlin, Z. Ye, J. Ledbetter, 2002, Nature Medicine.

Luciferase activity as a marker of tumor burden and as an indicator of tumor response to antineoplastic therapyin vivo

Lieping Chen, Lurong Zhang, K. Hellström, 1994, Clinical & Experimental Metastasis.

B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum.

J. Johnston, L. Chen, K. Hellström, 1994, Cancer research.

Phosphorylation of synthetic peptides by a tyrosine protein kinase from the particulate fraction of a lymphoma cell line.

E. Krebs, J. Casnellie, L. Pike, 1982, Proceedings of the National Academy of Sciences of the United States of America.

Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

J. Brown, G. Plowman, K. Hellström, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

J. Johnston, L. Chen, I. Hellstrom, 1994, The Journal of experimental medicine.

Inhibition of TGFβ1 Makes Nonimmunogenic Tumor Cells Effective for Therapeutic Vaccination

Pu Liu, K. Hellström, I. Hellström, 2009, Journal of immunotherapy.

Antitumor properties of vindesine-monoclonal antibody conjugates

R. W. Baldwin, J. Brown, R. G. Simmonds, 2004, Cancer Immunology, Immunotherapy.

Melanoma‐associated antigen p97 continues to be expressed after prolonged exposure of cells to specific antibody

J. Brown, K. Hellström, I. Hellström, 1983, International journal of cancer.

Identification of neurophysin immunoreactivity in hypothalamus by a monoclonal antibody to a carcinoma cell surface antigen.

G. Nilaver, E. Neuwelt, K. Hellström, 1990, Neuroendocrinology.

Development of a cancer DNA phenotype prior to tumor formation.

K. Hellström, D. C. Malins, E. Barker, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Costimulation of T cells for tumor immunity.

P. Linsley, Lieping Chen, L. Chen, 1993, Immunology today.

Cytotoxicity of human rosette‐forming blood lymphocytes on cultivated human tumor cells

K. Hellström, I. Hellström, H. Fudenberg, 1974, International journal of cancer.

Tumor vaccines--a reality at last?

K. Hellström, I. Hellström, 1998, Journal of immunotherapy.

Enhancement of tumor outgrowth by tumor‐associated blocking factors

I. Hellstrom, K. Hellström, I. Hellström, 1979, International journal of cancer.

Structural Studies of Human Melanoma-Associated Antigen p97

K. Hellström, I. Hellström, Joseph P. Brown, 1983 .

Tumor Immunology: An Overview

K. Hellström, I. Hellström, 1993, Annals of the New York Academy of Sciences.

On the Role of Costimulation in Tumor Immunity

P. Linsley, Lieping Chen, L. Chen, 1993, Annals of the New York Academy of Sciences.

Production of T‐cell lines with inhibitory or stimulatory activity against syngeneic tumors in vivo. A preliminary report

J. Mulé, I. Hellstrom, K. Hellström, 1981, International journal of cancer.

Specific anti‐tumor responses by cultured immune spleen cells. I. In vitro culture method and initial characterization of factors which block immune cell‐mediated cytotoxicity in vitro

K. Hellström, S. Pollack, K. Nelson, 1975, International journal of cancer.

Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.

M. Schummer, N. Urban, C. Drescher, 2012, Gynecologic oncology.

Clonal variation in expression of a human melanoma antigen defined by a monoclonal antibody.

K. Hellström, I. Hellström, M. Yeh, 1981, Journal of immunology.

Specific Killing of Human and Mouse Tumor Cells by Immunotoxins

P. Casellas, P. Gros, O. Gros, 1982 .

Antigens in Human Melanomas Detected by Using Monoclonal Antibodies as Probes

I. Hellstrom, K. Hellström, 1982 .

Cell Surface Antigens of Human Melanoma

I. Hellstrom, K. Hellström, Joseph P. Brown, 1983 .

Idiotypic interactions in immune responses to tumor-associated antigens.

G. Nepom, K. Hellström, V. Lee, 1986, Biochimica et biophysica acta.

Cyclophosphamide delays 3-methylcholanthrene sarcoma induction in mice

K. Hellström, I. Hellström, 1978, Nature.

Unique and common tumor‐specific transplantation antigens of chemically induced mouse sarcomas

K. Hellström, I. Hellström, Joseph P. Brown, 1978, International journal of cancer.

Increased lymphocyte‐mediated destruction of tumor cells in microcytotoxicity assays seen after addition of inhibitors of protein synthesis

K. Hellström, I. Hellström, J. Nepom, 1975, International journal of cancer.

Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

I. Hellstrom, K. Hellström, I. Hellström, 1974, Advances in immunology.

Some aspects of the immune defense against cancer I. In vitro studies on animal tumors

K. Hellström, I. Hellström, 1971, Cancer.

Studies on cellular immunity and its serum‐mediated inhibition in moloney‐virus‐induced mouse sarcomas

K. Hellström, I. Hellström, 1969, International journal of cancer.

In vitro studies of immune reactions against autochthonous and syngeneic mouse tumors induced by methylcholanthrene and plastic discs

K. Hellström, I. Hellström, G. Pierce, 1968, International journal of cancer.

Cell-bound immunity to autologous and syngeneic mouse tumors induced by methylcholanthrene and plastic discs.

I. Hellstrom, K. Hellström, I. Hellström, 1967, Science.

Chromosomal Studies on Primary Methylcholanthrene-Induced Sarcomas in the Mouse

K. Hellström, 1959 .

Anti-idiotypic tumor vaccines.

K. Hellström, I. Hellström, 1989, International reviews of immunology.

Cells from chemically induced mouse sarcomas retain tumor‐specific transplantation antigenicity during prolonged passage in vitro

K. Hellström, R. Walker, Ingegerd Hellstroöm, 1980, International journal of cancer.

Transplantation immunity to individually unique antigens of chemically induced bladder tumors in mice

K. Hellström, I. Hellström, W. Chapman, 1974, International journal of cancer.

Serum mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas.

H. Sjögren, K. Hellström, I. Hellström, 1970, Cellular immunology.

Colony inhibition studies on blocking and non‐blocking serum effects on cellular immunity to moloney sarcomas

K. Hellström, I. Hellström, 1970, International journal of cancer.

Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.

K. Lamborn, G. Denardo, S. Denardo, 1997, Anticancer research.

RADIOIMMUNOTHERAPY STUDIES IN BREAST CANCER

G. Denardo, S. Denardo, I. Hellstrom, 1992 .

Immunoconjugates and immunotoxins for therapy of solid tumors

P. Trail, K. Hellström, I. Hellström, 1996, Cancer Chemotherapy and Pharmacology.

CD83 Is a Sialic Acid-Binding Ig-Like Lectin (Siglec) Adhesion Receptor that Binds Monocytes and a Subset of Activated CD8+ T Cells1

J. Ledbetter, K. Hellström, I. Hellström, 2001, The Journal of Immunology.

Monocytes and a Subset of Activated CD 8 ( Siglec ) Adhesion Receptor that Binds CD 83 Is a Sialic Acid-Binding Ig-Like Lectin Hellström

J. Ledbetter, K. Hellström, I. Hellström, 2001 .

Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.

P. Trail, A. Bianchi, K. Hellström, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

The role of B7-2 (CD86) in tumour immunity.

L. Chen, K. Hellström, G. Yang, 1997, Expert opinion on investigational drugs.

Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.

Lieping Chen, I. Hellstrom, K. Hellström, 1994, Journal of immunology.

Antibody-mediated killing of human tumor cells by attached effector cells.

E. Lavie, K. Hellström, I. Hellström, 1988, Cancer research.

Lymphocyte‐dependent antibodies to antigen 3.1, a cell‐surface antigen expressed by a subgroup of human melanomas

K. Hellström, I. Hellström, M. Yeh, 1981, International journal of cancer.

Increase of lymphocyte‐mediated tumor‐cell destruction by certain patient sera

K. Hellström, I. Hellström, G. Warner, 1973, International journal of cancer.

Blocking of cell‐mediated tumor immunity by sera from patients with growing neoplasms

H. Sjögren, K. Hellström, I. Hellström, 1971, International journal of cancer.

Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens.

G. Heppner, J. Yang, I. Hellstrom, 1969, Proceedings of the National Academy of Sciences of the United States of America.

Metastatic conversion of cells by expression of human papillomavirus type 16 E6 and E7 genes.

D. Galloway, L. Chen, I. Hellstrom, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Immunological tolerance: "forbidden clones" allowed in tetraparental mice.

K. Hellström, I. Hellström, T. Wegmann, 1971, Proceedings of the National Academy of Sciences of the United States of America.

Neonatally Induced Allograft Tolerance may be mediated by Serum-borne Factors

A. Allison, K. Hellström, I. Hellström, 1971, Nature.

Immunological enhancement as studied by cell culture techniques.

K. Hellström, I. Hellström, Hellström Ke, 1970, Annual review of microbiology.

Human tumor antigens.

K. Hellström, I. Hellström, 1971, The New England journal of medicine.

Species restriction of a monoclonal antibody reacting with residues 130 to 137 in encephalitogenic myelin basic protein.

E. Alvord, J. Casnellie, K. Hellström, 1981, Science.

Monoclonal antibodies to two determinants of melanoma-antigen p97 act synergistically in complement-dependent cytotoxicity.

J. Brown, I. Hellstrom, K. Hellström, 1981, Journal of immunology.

The Role of Serum Factors (‘Blocking Antibodies’) as Mediators of Immunological Non‐Reactivity to Cellular Antigens

I. Hellstrom, K. Hellström, 2008 .

Adherent cells (macrophages?) in tumor-bearing mice suppress MLC responses.

P. Romero, K. Hellström, I. Hellström, 1981, Cellular immunology.

Overexpression of HER-2 in Ovarian Carcinomas 1

G. Goodman, K. Hellström, I. Hellström, 2001 .

Cutting Edge: CD83 Regulates the Development of Cellular Immunity1

A. Dahlin, J. Ledbetter, K. Hellström, 2002, The Journal of Immunology.

Role of epidermal growth factor receptor family members in growth and differentiation of breast carcinoma.

H. P. Fell, B. D. Cohen, S. Bacus, 1998, Biochemical Society symposium.

Workshop on monoclonal antibodies to human melanoma-associated antigens: findings of the Seattle group.

J. Brown, K. Hellström, I. Hellström, 1982, Hybridoma.

T cell immunity to tumor antigens.

K. Hellström, I. Hellström, 1998, Critical reviews in immunology.

Serotherapy of malignant disease.

I. Bernstein, K. Hellström, I. Hellström, 1976, The Medical clinics of North America.

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

Lieping Chen, I. Melero, A. Aruffo, 1997, Nature Medicine.

TRANSPLANTATION TOLERANCE AND ENHANCEMENT CONCEPTS AND QUESTIONS

K. Hellström, I. Hellström, W. Elkins, 1974, Transplantation.

Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.

I. Hellstrom, K. Hellström, I. Hellström, 1971, Proceedings of the National Academy of Sciences of the United States of America.

Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody

G. Nepom, K. Hellström, I. Hellström, 1983, Nature.

Abrogation of Cellular Immunity to Antigenically Foreign Mouse Embryonic Cells by a Serum Factor

K. Hellström, I. Hellström, J. Brawn, 1969, Nature.

RECENT STUDIES ON THE MECHANISMS OF THE ALLOGENEIC INHIBITION PHENOMENON *

K. Hellström, I. Hellström, Ingegerd Hellstrom, 1966 .

Colony inhibition of fibroblasts from chimeric dogs mediated by the dogs' own lymphocytes and specifically abrogated by their serum.

R. Storb, K. Hellström, I. Hellström, 1970, Proceedings of the National Academy of Sciences of the United States of America.

Cell‐mediated destruction of rous sarcomas in Japanese quails

K. Hellström, I. Hellström, K. Yamanouchi, 1972, International journal of cancer.

Cellular immunity and its serum‐mediated inhibition in shope‐virus‐induced rabbit papillomas

K. Hellström, I. Hellström, C. Evans, 1969, International journal of cancer.

Further studies on the ability of regressor sera to block cell‐mediated destruction of rous sarcomas

D. Lannin, K. Hellström, I. Hellström, 1974, International journal of cancer.

Serum effects on cell‐mediated destruction of rous sarcomas

K. Hellström, I. Hellström, M. Hayami, 1973, International journal of cancer.

Immunologie Defenses Against Cancer

K. Hellström, Ingecerd Hellström, 1970 .

CHAPTER 1 – Tumor Antigens

K. Hellström, Joseph P. Brown, 1979 .

Studies on cellular immunity to human neuroblastoma cells

K. Hellström, I. Hellström, A. H. Bill, 1970, International journal of cancer.

The role of immunological enhancement for the growth of autochthonous tumors.

K. Hellström, I. Hellström, 1971, Transplantation proceedings.

Serum factors in tumor‐free patients cancelling the blocking of cell‐mediated tumor immunity

K. Hellström, I. Hellström, G. Warner, 1971, International journal of cancer.

Human melanoma-associated antigen p97 is structurally and functionally related to transferrin

R. Doolittle, W. Dreyer, R. Hewick, 1982, Nature.

Oncogene‐associated tumor antigens as targets for immunotherapy

K. Hellström, I. Hellström, 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Suppression of cell-mediated cytotoxicity by lymphocytes from tumor-bearing animals.

K. Hellström, I. Hellström, M. Kall, 1976, Transplantation Proceedings.

Immunity to neuroblastomas and melanomas.

K. Hellström, I. Hellström, 1972, Annual Review of Medicine.

Differential processing and secretion of the melanoma-associated ME20 antigen.

W. C. Wang, K. Hellström, I. Hellström, 1994, Archives of biochemistry and biophysics.

Localization of melanoma-associated antigen p97 in cultured human melanoma, as visualized by light and electron microscopy.

K. Hellström, I. Hellström, W. Tilgen, 1983, The Journal of investigative dermatology.

Human tumor-associated antigens identified by monoclonal antibodies

K. Hellström, I. Hellström, Joseph P. Brown, 2004, Springer Seminars in Immunopathology.

Monoclonal antibodies to tumor antigens.

J. Brown, I. Hellstrom, K. Hellström, 1980, Contemporary topics in immunobiology.

Sequential studies on cell‐mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma

I. Hellstrom, K. Hellström, I. Hellström, 1973, International journal of cancer.

Elution of “blocking factors” from human tumors, capable of abrogating tumor‐cell destruction by specifically immune lymphocytes

K. Hellström, I. Hellström, G. Warner, 1972, International journal of cancer.

Tumor-associated blocking factors: isolation from sera of tumor-bearing mice.

K. Hellström, I. Hellström, J. Tamerius, 1976, Journal of immunology.

Suppressor mechanisms in tumor immunity

G. Nepom, K. Hellström, I. Hellström, 1983, Experientia.

Blocking (suppressor) factors, immune complexes, and extracorporeal immunoadsorption in tumor immunity.

K. Hellström, I. Hellström, H. Snyder, 1985, Contemporary topics in immunobiology.

Specific blocking factors--are they important?

I. Hellstrom, K. Hellström, I. Hellström, 1977, Biochimica et biophysica acta.

CELL‐MEDIATED IMMUNITY TO MOUSE TUMORS: SOME RECENT FINDINGS *

K. Hellström, I. Hellström, 1976, Annals of the New York Academy of Sciences.

BLOCKING FACTORS IN TUMOR IMMUNITY AND ALLOGRAFT TOLERANCE

I. Bernstein, K. Hellström, I. Hellström, 1974 .

Newer concepts of cancer of the colon and rectum: Cellular immunity to human colonic carcinomas

K. Hellström, I. Hellström, 1972, Diseases of the colon and rectum.

Cell‐mediated immunity against antigens common to human colonic carcinomas and fetal gut Epithelium

K. Hellström, I. Hellström, T. Shepard, 1970, International journal of cancer.

Cytotoxic effect of lymphocytes from pregnant mice on cultivated tumor cells. I. Specificity, nature of effector cells and blocking by serum

K. Hellström, I. Hellström, 1975, International journal of cancer.

Cell-Mediated Immunity to Human Tumor Antigens

K. Hellström, I. Hellström, G. Warner, 1971 .

In vitro sensitization to embryonic antigens

K. Hellström, I. Hellström, K. Friend, 1976, International journal of cancer.

The Role of Cell-Mediated Immunity in Control and Growth of Tumors

I. Hellstrom, K. Hellström, 1974 .

Leukocyte-mediated reactivity to human tumors as detected by the leukocyte adherence inhibition test. I. Demonstration of tumor type-specific reactions.

G. van Belle, K. Hellström, I. Hellström, 1977, American journal of clinical pathology.

Purification and partial characterization of a tumor-specific blocking factor from sera of mice with growing chemically induced sarcomas.

K. Hellström, I. Hellström, J. Nepom, 1976, Journal of immunology.

Some recent studies on cellular immunity to human melanomas.

K. Hellström, I. Hellström, 1973, Federation proceedings.

Demonstration of tumor‐associated immunity with a leukocyte adherence inhibition (LAI) assay

K. Hellström, I. Hellström, G. Shantz, 1976, International journal of cancer.

Cell‐mediated immune reactions to tumor antigens with particular emphasis on immunity to human neoplasms

K. Hellström, I. Hellström, 1974, Cancer.

Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies.

J. Brown, I. Hellstrom, K. Hellstrom, 1980, The Journal of biological chemistry.

Immunological and Immunogenetic Aspects of Tumor Transplantation

K. Hellström, G. Möller, 1965 .

Demonstration of Syngeneic Preference In Vitro

K. Hellström, I. Hellström, G. Haughton, 1964, Nature.

Evidence that blocking factors in the sera of multiparous mice are associated with immunoglobulins

K. Hellström, I. Hellström, J. Tamerius, 1975, International journal of cancer.

Cytotoxic effect of lymphocytes from pregnant mice on cultivated tumor cells. II. Blocking and unblocking of cytotoxicity

K. Hellström, I. Hellström, 1975, International journal of cancer.

The X-ray structure of an anti-tumour antibody in complex with antigen

J. Bajorath, P. Jeffrey, S. Sheriff, 1995, Nature Structural Biology.

Specific sensitization of lymphocytes to tumor antigens by Co‐cultivation with peritoneal cells exposed to such antigens

K. Hellström, I. Hellström, 1976, International journal of cancer.

A microassay for antibody binding to tumor cell surface antigens using 125I-labelled protein a from Staphylococcus aureus.

J. Brown, K. Hellström, Joseph P. Brown, 1977, Journal of immunological methods.

Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment.

H. Ditzel, J. Jensenius, A. Svejgaard, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates.

P. Trail, I. Hellstrom, K. Hellström, 1993, Science.

Development and activities of the BR96-doxorubicin immunoconjugate.

K. Hellström, I. Hellström, P. Senter, 2001, Methods in molecular biology.

Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.

P. Trail, I. Hellstrom, K. Hellström, 1997, Cancer research.

CD83 is an I-type lectin adhesion receptor that binds monocytes and a subset of activated CD8+ T cells [corrected].

J. Ledbetter, K. Hellström, I. Hellström, 2001, Journal of immunology.

AUTOANTIBODIES TO MESOTHELIN IN INFERTILITY a,,b,,c

Pu Liu, J. Luborsky, I. Hellstrom, 2012 .

Immunoconjugates and immunotoxins for therapy of carcinomas.

P. Trail, K. Hellström, I. Hellström, 1995, Advances in pharmacology.

Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.

K. Hellström, I. Hellström, Huafeng Wei, 2012, Gynecologic oncology.

The need to establish whether the leukocyte adherence inhibition test is a reliable assay of tumor immunity in humans.

K. Hellström, I. Hellström, 1979, Cancer research.

Recent advances in antitumor vaccines.

K. Hellström, I. Hellström, S. Hu, 1992, Biotechnology.

Anti-idiotypes and cancer therapy

K. Hellström, V. Lee, 1988 .

Anti-murine leukemia virus (mulv) activity of immuno- globulins eluted from the renal glomeruli of multiparous mice. Abstr.

K. Hellström, R. Nowinski, J. Tamerius, 1976 .

Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population

J. Kant, K. Hellström, I. Hellström, 1978, The Journal of experimental medicine.

Cell Types Identified in Tissue Cultures of Epithelium of the Rabbit Fallopian Tube

K. Hellström, O. Nilsson, 1957, Acta obstetricia et gynecologica Scandinavica.

Antitumor effect of whole-body X-irradiation: possible role of an X-ray-sensitive T suppressor cell population.

K. Hellström, I. Hellström, 1979, Transplantation proceedings.

Evidence that tumor antigens enhance tumor growth in vivo by interacting with a radiosensitive (suppressor?) cell population.

I. Hellstrom, K. Hellström, I. Hellström, 1978, Proceedings of the National Academy of Sciences of the United States of America.

Cyclophosphamide potentiates the antitumor activity of v-p97NY.

K. Hellström, I. Hellström, C. Estin, 1989, Cellular immunology.

Tumor-specific idiotopes on suppressor factors and suppressor cells revealed by monoclonal anti-idiotope antibodies.

K. Hellström, I. Hellström, W. J. Halliday, 1987, Cellular immunology.

An isotope-release assay and terminal-labeling assay for measuring cell-mediated allograft and tumor immunity to small numbers of adherent target cells.

I. Hellstrom, K. Hellström, I. Hellström, 1978, Journal of immunological methods.

Antibody response of mice to chemically induced tumors.

J. Brown, I. Hellstrom, K. Hellström, 1978, Proceedings of the National Academy of Sciences of the United States of America.

Anti-idiotypic antibodies and the induction of specific tumor immunity

G. Nepom, K. Hellström, 2004, Cancer and Metastasis Reviews.

Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells.

K. Hellström, E. George, J. Forstrom, 1987, Journal of immunology.

Monoclonal antiidiotypic antibodies related to a murine oncofetal bladder tumor antigen induce specific cell-mediated tumor immunity.

K. Hellström, I. Hellström, W. J. Halliday, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice.

S. Holbeck, G. Nepom, K. Hellström, 1984, Proceedings of the National Academy of Sciences of the United States of America.

T-T hybridoma product specifically suppresses tumor immunity.

K. Hellström, I. Hellström, J. Cory, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Antigen-specific purification of blocking factors from sera of mice with chemically induced tumors.

K. Hellström, I. Hellström, J. Nepom, 1977, Proceedings of the National Academy of Sciences of the United States of America.

Site‐directed delivery of anthracyclines for treatment of cancer

P. Trail, K. Hellström, D. Willner, 1995 .

Allograft tolerance: presumptive evidence that serum factors from tolerant animals that block lymphocyte-mediated immunity in vitro are soluble antigen-antibody complexes.

I. Bernstein, R. Hargreaves, K. Hellström, 1973, Proceedings of the National Academy of Sciences of the United States of America.

Cellular immunity and blocking serum activity in chimeric mice.

I. Hellstrom, K. Hellström, I. Hellström, 1973, Cellular immunology.

A monoclonal antibody recognizing cytoskeletal keratins of stratified epithelia and bladder carcinomas.

K. Hellström, I. Hellström, S. Settle, 1985, Experimental cell research.

Syngeneic preference and allogeneic inhibition.

K. Hellström, I. Hellström, Hellström Ke, 1965, The Wistar Institute symposium monograph.

Immunization against ethylnitrosourea-induced autochthonous neurogenic rat tumours.

G. van Belle, A. Spence, K. Hellström, 1979, British Journal of Cancer.

Overexpression of HER-2 in ovarian carcinomas.

G. Goodman, Y. Yang, Yi Yang, 2001, Cancer research.

CD83 is a sialic acid-binding Ig-like lectin (Siglec) adhesion receptor that binds monocytes and a subset of activated CD8+ T cells

J. Ledbetter, K. Hellström, I. Hellström, 2009, The Journal of Immunology.

Studies on immunity to autochthonous mouse tumors.

K. Hellström, I. Hellström, A. Fefer, 1969, Transplantation proceedings.

Differential Behaviour of Transplanted Mouse Lymphoma Lines in Genetically Compatible Homozygous and F1 Hybrid Mice

K. Hellström, 1963, Nature.

Allogeneic Inhibition and Its Possible Relation to Cell-Bound Immunity in Vitro

K. Hellström, I. Hellström, 1967 .

Studies on allogeneic inhibition I. Differential behavior of mouse tumors transplanted to homozygous and F1 hybrid hosts

K. Hellström, 1966 .

Allogeneic Inhibition of Tumour Cells by in vitro Contact with Cells Containing Foreign H-2 Antigens

K. Hellström, I. Hellström, C. Bergheden, 1965, Nature.

Some aspects of the cellular and humoral immune response to tumour antigens.

K. Hellström, I. Hellström, 1972, Triangle; the Sandoz journal of medical science.

Development of tumor lines with decreased sensitivity to allogeneic inhibition.

K. Hellström, 1966, Experimental Cell Research.

Possible Use of H-2 Antigens as Positive Selective Markers in Heterogeneous Cell Populations

K. Hellström, 1964, Nature.

Studies on the mechanism of isoantigenic variant formation in heterozygous mouse tumors. II. Behavior of H-2 antigens D and K: cytotoxic tests on mouse lymphomas.

K. Hellström, 1961 .

CELL‐MEDIATED REACTIVITY AND SERUM BLOCKING ACTIVITY IN TOLERANT RATS STUDIES ON TEN RATS OPERATIONALLY TOLERANT TO SKIN ALLOGRAFTS USING SEVERAL INDPENDENT ASSAYS

I. Bernstein, K. Hellström, P. W. Wright, 1974, Transplantation.

Monoclonal antiidiotypic antibodies related to the p97 human melanoma antigen.

M. Kahn, K. Hellström, I. Hellström, 1989, Cancer research.

Cloning and expression of the tumor-associated antigen L6.

G. Schieven, A. Aruffo, I. Hellstrom, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Identification of a novel serum protein secreted by lung carcinoma cells.

P. Linsley, J. Brown, E. Tolentino, 1986, Biochemistry.

CELL-MEDIATED IMMUNITY AND BLOCKING SERUM ACTIVITY TO TOLERATED ALLOGRAFTS IN RATS

K. Hellström, I. Hellström, S. Bansal, 1973, The Journal of experimental medicine.

Does perfusion with treated plasma cure cancer?

K. Hellström, I. Hellström, 1981, The New England journal of medicine.

Studies on allogeneic inhibition III. Inhibition of mouse tumor cell colony formation in vitro by contact with lymphoid cells containing foreign H‐2 antigens

I. Hellstrom, K. Hellström, I. Hellström, 1967 .

Studies on allogeneic inhibition II. Inhibition of mouse tumor cell growth by In vitro contact with cells containing foreign H‐2 antigens

K. Hellström, C. Bergheden, 1966 .

Immunological and Immunogenetic Aspects of Tumor Transplantation (Part 1 of 3)

K. Hellström, G. Möller, 1965 .

Human tumor-specific antigens.

K. Hellström, I. Hellström, G. Pierce, 1969, Surgery.

A highly sensitive and reproducible microcytotoxicity assay for demonstrating cytotoxic antibodies to cell surface antigens.

J. Brown, K. Hellström, I. Hellström, 1978, Journal of immunological methods.

MONOCLONAL ANTIBODIES TO HUMAN MELANOMA-ASSOCIATED ANTIGEN p97

I. Hellstrom, K. Hellström, Joseph P. Brown, 1983 .

Cell‐mediated suppression of tumor immunity has a non‐specific component. I. Evidence from transplantation tests

K. Hellström, I. Hellström, 1981, International journal of cancer.

B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes

Lieping Chen, J. Johnston, L. Chen, 1996, The Journal of experimental medicine.

A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab*

J. Bajorath, W. Huse, K. Hellström, 1996, The Journal of Biological Chemistry.

Tumor-enhancing suppressor activator T cells in spleens and thymuses of tumor immune mice.

I. Bernstein, K. Hellström, I. Hellström, 1979, Proceedings of the National Academy of Sciences of the United States of America.

Human and Mouse CD137 Have Predominantly Different Binding CRDs to Their Respective Ligands

Yanlin Zhao, K. Hellström, I. Hellström, 2014, PloS one.

Immune Mechanisms Are Major Players in Cancer

K. Hellström, I. Hellström, 2015 .

Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas.

K. Hellström, I. Hellström, P. Beaumier, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Chromosomal abnormalities induced in vitro by extracts of mouse allogeneic lymphocytes.

P. Fialkow, K. Hellström, I. Hellström, 1968, Experimental cell research.

Cellular immunity and blocking antibodies to tumors.

K. Hellström, I. Hellström, 1971, Journal of the Reticuloendothelial Society.

Five Melanoma-Associated Antigens Identified by Monoclonal Antibodies

I. Hellstrom, K. Hellström, Joseph P. Brown, 1982 .

Treatment with monoclonal antibodies (mAbs) against the 4-1BB T-cell activation molecule eradicate established tumors

Lieping Chen, I. Melero, A. Aruffo, 1997 .

Expression of neurophysin-related precursor in cell membranes of a small-cell lung carcinoma.

Y. Loh, H. V. Van Tol, G. Nilaver, 1990, Proceedings of the National Academy of Sciences of the United States of America.

B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes.

K. Hellström, G. Yang, M. Mizuno, 1997, Journal of immunology.

Antigen-specific suppressor ("blocking") factors in tumor immunity.

K. Hellström, I. Hellström, K. Nelson, 1983, Biomembranes.

In situ adenovirus vaccination engages T effector cells against cancer.

Y. Liu, S. Tuve, S. Roffler, 2009, Vaccine.

Presence of both cell-mediated immunity and serum-blocking factors in rat renal allografts "enhanced" by passive immunization.

K. Hellström, I. Hellström, F. Fitch, 1971, Transplantation.

Different responses of lymphoid cells from tumor-bearing as compared to tumor-immunized mice when sensitized to tumor specific antigens in vitro.

K. Hellström, I. Hellström, M. Kall, 1975, Proceedings of the National Academy of Sciences of the United States of America.

Human melanotransferrin (p97) has only one functional iron‐binding site

H. Baker, E. Baker, M. Kahn, 1992, FEBS letters.

Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas.

T. Wheeler, M. Sayeeduddin, K. Hellström, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Transfected mouse melanoma lines that express various levels of human melanoma-associated antigen p97.

M. Kahn, K. Hellström, I. Hellström, 1989, Journal of the National Cancer Institute.

Cancer vaccines: challenges and potential solutions.

K. Hellström, I. Hellström, P. Gladstone, 1997, Molecular medicine today.

Protective Immunity Induced by B7/CD28=Costimulated y6 T Cells to the EL-4 Lymphoma in Allogenic Athymic Mice

J. Johnston, K. Hellström, S. A. Newby, 2001 .

An In Vitro System Combining Tumor Cells and Lymphocytes to Predict the In Vivo Response of Immunomodulatory Antibodies

K. Hellström, I. Hellström, M. Dai, 2020 .

Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.

E. Neuwelt, P. Trail, K. Hellström, 2000, Neurosurgery.

Cell‐mediated reactivity to antigens shared by moloney‐virus‐induced lymphomas (LSTRA) and certain 3‐methylcholanthrene‐induced mouse sarcomas

I. Bernstein, J. Brown, I. Hellstrom, 1979, International journal of cancer.

Indirect 125I-labeled protein A assay for monoclonal antibodies to cell-surface antigens.

J. Brown, K. Hellström, I. Hellström, 1983, Methods in enzymology.

MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis.

R Weissleder, R. Weissleder, G. Nilaver, 1996, AJNR. American journal of neuroradiology.

Allogeneic inhibition in vitro.

K. Hellström, I. Hellström, 1966, Annales medicinae experimentalis et biologiae Fenniae.

In vitro generation of primary and secondary cytotoxic cell‐mediated immune responses to chemically induced mouse sarcomas

K. Hellström, I. Hellström, Karl Erik Hellström, 1976, International journal of cancer.

Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

G. Klein, E. Klein, K. Hellström, 1960, Cancer research.

Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma‐associated antigen p97

P. Casellas, J. Brown, P. Gros, 1982, International journal of cancer.

Application of a filamentous phage pVIII fusion protein system suitable for efficient production, screening, and mutagenesis of F(ab) antibody fragments.

W. Huse, K. Hellström, I. Hellström, 1992, Journal of immunology.

Cellular immunity to tumor-associated antigens in man.

K. Hellström, I. Hellström, 1977, New England Journal of Medicine.

Assignment of the gene for human melanoma-associated antigen p97 to chromosome 3

H. Sussman, G. Plowman, K. Hellström, 1983, Nature.

Some aspects of the immune defense against cancer II. In vitro studies on human tumors

K. Hellström, I. Hellström, 1971, Cancer.

Variations in the sensitivity to polyoma virus in cultures of polyoma tumors and other neoplasms.

K. Hellström, I. Hellström, 1962 .

Two human tumor‐associated antigens, p155 and p210, detected by monoclonal antibodies

J. Brown, I. Hellstrom, K. Hellström, 1981, International journal of cancer.

Costimulation of T-cell-mediated tumor immunity

Lieping Chen, K. Hellström, I. Hellström, 1996, Cancer Chemotherapy and Pharmacology.

In vitro synthesis of tumor‐specific factors with blocking and antibody‐dependent cellular cytotoxicity (ADC) activities

K. Hellström, S. Pollack, K. Nelson, 1975, International journal of cancer.

Suppressor pathways in tumor immunity: A requirement for Qa‐1 positive tumor‐bearer spleen t cells in suppression of the afferent immune response to tumor antigens

J. Mulé, K. Hellström, I. Hellström, 1981, International journal of cancer.

Dexamethasone decreases the delivery of tumor-specific monoclonal antibody to both intracerebral and subcutaneous tumor xenografts.

E. Neuwelt, K. Hellström, I. Hellström, 1993, Neurosurgery.

Long-term transplantability and morphological stability of three experimentally induced urinary bladder carcinomas in rats.

K. Hellström, W. Chapman, T. Wahlström, 1976, Cancer research.

Long-TermTransplantabilityand MorphologicalStabilityof Three ExperimentallyInducedUrinaryBladderCarcinomas in Rats1

K. Hellström, W. Chapman, T. Wahlström, 1976 .

Role of CD2 cross‐linking in cytoplasmic calcium responses and T cell activation

P. Rabinovitch, C. June, J. Ledbetter, 1988, European journal of immunology.

Techniques for Characterization of Leucocyte Antigens and Utilization of Antibodies in Therapy

H. Tanke, J. Ploem, K. Lennert, 1984 .

Antibody deposition in tumor in relation to blood clearance using a nephrectomized mouse model

J. Eary, W. Nelp, K. Krohn, 1985 .